SCHEMBL5724422

SCHEMBL5724422

O=C1CCC(=O)N1Cc1csc(N2CC(O)C2)n1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 15/20 0.33
HRH3 Q9Y5N1 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
AOC3 Q16853 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724068 0.82 LMNA (0.43) DNM1L
SCHEMBL5723791 0.81 HRH3 (0.32) DNM1LHRH3HCRTR2
SCHEMBL5724161 0.81 DNM1L (0.36) DNM1LHRH3
SCHEMBL5724279 0.77 HRH3 (0.43) DNM1LHRH3AOC3
SCHEMBL5723984 0.72 DNM1L (0.33) DNM1LHCRTR1HCRTR2
SCHEMBL5724236 0.70 HRH3 (0.36) DNM1LHRH3AOC3
SCHEMBL5724065 0.68 KDM4E (0.55) DNM1L
SCHEMBL5724314 0.68 F2RL3 (0.34) HRH3
SCHEMBL16717802 0.67 RAB9A (0.34)
SCHEMBL13270746 0.67 L3MBTL1 (0.42) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD DNM1L 765/4885HRH3 3678/4885HCRTR1 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.